GeoVax Labs, Inc. New Stock Prediction
AI-powered sentiment analysis and prediction trends for GOVX, updated each market day.
GOVX AI Sentiment
AI predicts GeoVax Labs, Inc. New stock is likely to decrease over the next 10 market days.
Prediction date: May 20, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About GeoVax Labs, Inc. New
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
Sector
Exchange
Market Cap
$3,644,638
Cap Tier
Employees
19
Headquarters
SMYRNA, GA
Listed Since
Feb. 1, 1995
Website
GOVX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
GOVX Volatility
GeoVax Labs, Inc. New has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
